Annual CFF
$21.04 M
+$20.56 M+4291.86%
31 December 2023
Summary:
Entrada Therapeutics annual cash flow from financing activities is currently $21.04 million, with the most recent change of +$20.56 million (+4291.86%) on 31 December 2023. During the last 3 years, it has fallen by -$286.42 million (-93.16%). TRDA annual CFF is now -93.16% below its all-time high of $307.46 million, reached on 31 December 2021.TRDA Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$11.00 K
-$101.38 M-100.01%
30 September 2024
Summary:
Entrada Therapeutics quarterly cash flow from financing activities is currently -$11.00 thousand, with the most recent change of -$101.38 million (-100.01%) on 30 September 2024. Over the past year, it has dropped by -$701.00 thousand (-101.59%). TRDA quarterly CFF is now -100.01% below its all-time high of $190.75 million, reached on 31 December 2021.TRDA Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$102.25 M
-$379.00 K-0.37%
30 September 2024
Summary:
Entrada Therapeutics TTM cash flow from financing activities is currently $102.25 million, with the most recent change of -$379.00 thousand (-0.37%) on 30 September 2024. Over the past year, it has increased by +$81.22 million (+386.06%). TRDA TTM CFF is now -66.74% below its all-time high of $307.46 million, reached on 31 December 2021.TRDA TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TRDA Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | -101.6% | +386.1% |
| 3 y3 years | -93.2% | -100.0% | -66.7% |
| 5 y5 years | +10000.0% | - | - |
TRDA Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -93.2% | +4291.9% | -100.0% | at low | -66.7% | >+9999.0% |
| 5 y | 5 years | -93.2% | >+9999.0% | -100.0% | at low | -66.7% | >+9999.0% |
| alltime | all time | -93.2% | >+9999.0% | -100.0% | at low | -66.7% | >+9999.0% |
Entrada Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$11.00 K(-100.0%) | $102.25 M(-0.4%) |
| June 2024 | - | $101.37 M(>+9900.0%) | $102.63 M(+5912.4%) |
| Mar 2024 | - | $206.00 K(-70.1%) | $1.71 M(-91.9%) |
| Dec 2023 | $21.04 M(+4291.9%) | $690.00 K(+87.5%) | $21.04 M(+1.6%) |
| Sept 2023 | - | $368.00 K(-16.9%) | $20.70 M(+1.5%) |
| June 2023 | - | $443.00 K(-97.7%) | $20.40 M(+2.2%) |
| Mar 2023 | - | $19.54 M(+5357.0%) | $19.96 M(+4068.1%) |
| Dec 2022 | $479.00 K | $358.00 K(+496.7%) | $479.00 K(-99.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2022 | - | $60.00 K(+445.5%) | $190.88 M(-0.0%) |
| June 2022 | - | $11.00 K(-78.0%) | $190.92 M(-0.1%) |
| Mar 2022 | - | $50.00 K(-100.0%) | $191.13 M(-37.8%) |
| Dec 2021 | $307.46 M(+513.8%) | $190.75 M(>+9900.0%) | $307.46 M(+163.4%) |
| Sept 2021 | - | $106.00 K(-50.7%) | $116.71 M(+0.1%) |
| June 2021 | - | $215.00 K(-99.8%) | $116.60 M(+0.2%) |
| Mar 2021 | - | $116.39 M | $116.39 M |
| Dec 2020 | $50.09 M(>+9900.0%) | - | - |
| Dec 2019 | $38.00 K | - | - |
FAQ
- What is Entrada Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Entrada Therapeutics?
- What is Entrada Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Entrada Therapeutics?
- What is Entrada Therapeutics quarterly CFF year-on-year change?
- What is Entrada Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Entrada Therapeutics?
- What is Entrada Therapeutics TTM CFF year-on-year change?
What is Entrada Therapeutics annual cash flow from financing activities?
The current annual CFF of TRDA is $21.04 M
What is the all time high annual CFF for Entrada Therapeutics?
Entrada Therapeutics all-time high annual cash flow from financing activities is $307.46 M
What is Entrada Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of TRDA is -$11.00 K
What is the all time high quarterly CFF for Entrada Therapeutics?
Entrada Therapeutics all-time high quarterly cash flow from financing activities is $190.75 M
What is Entrada Therapeutics quarterly CFF year-on-year change?
Over the past year, TRDA quarterly cash flow from financing activities has changed by -$701.00 K (-101.59%)
What is Entrada Therapeutics TTM cash flow from financing activities?
The current TTM CFF of TRDA is $102.25 M
What is the all time high TTM CFF for Entrada Therapeutics?
Entrada Therapeutics all-time high TTM cash flow from financing activities is $307.46 M
What is Entrada Therapeutics TTM CFF year-on-year change?
Over the past year, TRDA TTM cash flow from financing activities has changed by +$81.22 M (+386.06%)